$Bob's and Jbem's Bitchin' Bios

[BioSpecialist]

RDHL (MC $61 M) FDA deicison on Feb 3 // 2 more NDA filings in 2014 // Float 4 M

RDHL is another brutally Underpriced and Unknown Biotech Stock .
Here are the reasons why this low float Gem is a MUST HAVE for every Biotech investor :

1) Very Promising Pipeline with multiple potential Blockbusters
2) FDA decision for first Drug (migraine) on February 3
3) Another 2x NDA Filings soon one in 1Q and one in 2H 2014
4) Another 2 Drugs in Phase 3
5) Very low Burn-rate of only $10 M per year
6) Enough Cash untill mid 2015 Excluding cash from new Partnerships
7) Dirt Cheap with a Market cap of just $61 M
8) Ultra low float with only 4.2 M shares
9) Top Management ( they have one of the most successful director in the pharma area on their board , see below the info to this guy )


I think this low float stock has everything to hit minimum $50++ within 2014 .For me RDHL is currently my top favorite stock in the Biotech sector . GL




Redhill (RDHL)

Market Cap: $61 M
Cash: $14.7 M
Price: $9.80

Shares Out: 6.3 M (Management alone holding over 2.6 M shrs)
Float: 4.2 M


Presentation September 2013
http://files.shareholder.com/downloads/AMDA-1C0OBF/2736607566x0x690006/36cdf135-d2c9-4ce8-88d4-df998ade2152/RedHill%20Biopharma%20Presentation%20September%202013.pdf





Dan Suesskind, Director

Mr. Suesskind, who served 31 years as CFO of Teva Pharmaceutical Industries (NYSE: TEVA) until 2008, had played a pivotal role in the strategic activities of the Israeli generic pharmaceuticals giant, including the acquisition of more than 30 companies. During that period, Teva grew from a small Israeli company with a market cap of $37 million, into a leading global company with a market cap exceeding $34 billion in 2008. Mr. Suesskind is a member of Teva’s board of directors.